Register for our free email digests:
Latest From Savara Inc.
Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
Among the antibiotics that have garnered a qualified infectious disease product designation, a collection of late-stage products are targeted at local delivery, especially inhaled and vaginal formulations.
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
- Nanotechnology, Chips, etc.
- Drug Delivery
- Therapeutic Areas
- Infectious & Viral Diseases
- Respiratory, Pulmonary
- Aravas Inc.
- North America
- Parent & Subsidiaries
- Savara Inc.
- Senior Management
Rob Neville, Pres. & CEO
Dave Lowrance, CFO
Taneli Jouhikainen, MD, PhD, COO
Chris Marich, Head, Bus. Operations
Cecilia Ganslandt, MD, Head, Medical Affairs
Kenny Frazier, Head of Clinical Dev.
- Contact Info
Phone: (512) 961-1891
900 S. Capital of Texas Hwy., Ste. 150
Austin, TX 78746
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.